The Fellow on Call: The Heme/Onc Podcast

Dr. Matthew Abramson, Dr. Timothy Yau, and Dr. Scott Stockholm discuss immune checkpoint inhibitor-related AKIs and hypomagnesia in patients. They cover topics such as the mechanism and etiology of immune checkpoint inhibitor-associated AKIs, how to work them up and treat them, and the use of ICI in patients with kidney transplants. They also discuss the symptoms and management of hypomagnesemia, as well as drugs associated with it.

It’s been a long road, but incredibly educational journey, through our Myeloma Series. We finish off our series with a bang by sitting down with Multiple Myeloma Superstar, Dr. Manni Mohyuddin. In this episode, Dr. Mohyuddin takes us through his approach to complex decisions in the care of patients with myeloma, highlighting that myeloma treatment is an art in which we take imperfect data and try to make the best decisions for our patients. Trust us, folks, you do NOT want to miss this episode! Content:- How does Dr. Mohyuddin approach treatment of myeloma? - How does he approach maintenance? - What is the role of transplant in patients with myeloma? - Is there a role of MRD testing? - What is his approach to relapsed/refractory setting? - What about the use of agents like venetoclax or VDT-PACE?- A discussion about role of CAR-T therapy- Approach to bridging strategies ** A huge THANK YOU to our guest, Dr. Manni Mohyuddin! ** This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co ** Help us as we continue to grow our show by filling out this BRIEF survey! Link: https://forms.gle/KBhDRTGBqRJ1CgnK7Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In episode 046, we discussed the fundamentals of transplant in the treatment of patients with multiple myeloma. This week, we sit down with two incredible hematologists who specialize in transplant to discuss the real-life decision-making that goes into evaluating each patient. We are so excited to welcome two special guests this week, Dr. Shonali Midha and Dr. Amar Kelkar, joining us from the Dana-Farber Cancer Institute in Boston!Content:- What goes into determining if a patient is transplant eligible?- What counseling is provided to patients? - Approach to melphalan dosing- How does apheresis work? - What agents are used to help mobilize stem cells? - How many stem cells do we need to collect?- Does how much therapy one has received affect their collection? - Is there still a role for transplant in today's world?- Is there a role for an "MRD-adapted" approach to treatment?- Is there a role for a second transplant in patients who have relapsed?- Is there a role for allogeneic stem cell transplants in myeloma?A huge THANK YOU to our guests, Dr. Shonali Midha and Dr. Amar Kelkar, both of the Dana-Farber Cancer Institute!Help us as we continue to grow our show by filling out this BRIEF survey! Link: https://forms.gle/KBhDRTGBqRJ1CgnK7Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

We continue our myeloma series, transitioning our discussion from autologous stem cell transplant to maintenance therapy for myeloma.Content:- Why do we use revlimid (lenalidomide) maintenance?- What about in high risk patients?- What is the role of MRD testing?- What about daratumumab in the maintenance setting? This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co.Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this continuation of our myeloma series, we discuss all the key principles and data surrounding autologous stem cell transplant in myeloma. We provide a succinct summary of key trials in this space that will give you a deep understanding of the field. Content:- What are all these cooperative groups in the studies?- What are some of the important trials that show us the benefit of autologous stem cell transplant? - Should transplant be done early or should it be delayed? What does it matter? - We translate the data/guidelines into what this means for patients in real-life- How do we approach transplant in high risk patients in myeloma and what are the guidelines about tandem transplant? This episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co.Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this episode, we start with a little bit of story time about the history of myeloma treatments and how we got to the present day. We then finish off the episode with how this information helped us treat transplant ineligible patients. Content:- What is the history of myeloma treatment? How did we get to where we are today? - How do we approach treatment in transplant ineligible patients? - What are the key trials that every fellow needs to know? - Links to key trialsWant to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this continuation of our myeloma series, we build on our prior discussion about myeloma pharmacology, this time discussing how to select the optimal regimen for treatment of our patients.Content:- What are the phases of multiple myeloma treatment?- How do we determine transplant eligibility?- What does doublet, triplet, and quadruplet therapy mean? - What categorizes "high risk" myeloma?- What are the current standards of care for transplant eligible patients? - Where does "CyBorD" fit in for treatment? - When do we consider adding daratumumab? - Links to key trialsThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co.Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!Content:- What are common drugs we use in "triplet regimens"? "quadruple therapy"? - What considerations must we take into account when prescribing commonly used medications in myeloma? - How should we counsel our patients? - What about supportive care?- How and when do we make dose adjustments? - This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not seeWant to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

The podcast discusses the progression from MGUS to multiple myeloma and how to risk stratify patients with a myeloma diagnosis. It explores the role of FISH/karyotype in risk stratification and how to gauge disease response and treatment response. The episode also touches on the importance of minimal residual disease (MRD) in myeloma.

In today’s episode, we continue our myeloma series, this time we’ll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!Content:- Defining MGUS- Discussing risk of progression of MGUS to MM- How to interpret free light chains in renal failure- How do we monitor MGUS patients?- When do we do additional testing in MGUS?- What is smoldering myeloma?- What are myeloma defining events?- How do we risk stratify SM patients?- How do we monitor SM patients? Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesThis episode has been sponsored by Primum. To sign up for a free account, check out: tfoc.primum.co Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast